2cureX ROE

Mitä 2cureX tekee? 2cureX AB is a healthcare company based in Landskrona, Sweden, listed on the Stockholm Stock Exchange under the ticker 2CUREX.ST. The company went public via an IPO on November 24, 2017. 2cureX AB specializes in research and development of anti-cancer treatments, focusing on diagnostic substances to guide cancer patient treatment decisions. The company's primary product candidate, IndiTreat - CRC, is designed to optimize treatment for colorectal cancer patients. This technology involves creating three-dimensional micro-tumors from patient tumor samples to test various chemotherapies and experimental treatments. 2cureX AB also has additional product candidates in its pipeline, including IndiTreat - OVA for ovarian cancer treatment and IndiTreat - KDN for kidney cancer treatment. The company operates through its subsidiary 2cureX A/S. While the company's website is https://www.2curex.com/, the provided information does not include details about its founding year, key personnel, specific financial figures, or the exact nature of its research methodologies beyond the described product candidates. The company's operations are centered on developing diagnostic tools to personalize cancer treatment approaches. 2cureX on yksi Eurpooliin suosituimmista yhtiöistä.